gip/glp 1-agonist tirzepatide Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of | Cardiovascular Diabetology Tirzepatide is an imbalanced and

Excess adipose tissue produces inflammatory compounds called adipokines, which amplify joint inflammation and disease activity

Taking differences in quantities of peptide administered via the intestine compared with i.v

Acid reflux , bloating , and sulfur burps are additional complaints

The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob mice

Protein supplementation during GLP-1 treatment can further support muscle preservation

Future research is needed to study the use of obesity treatments other than AOM liraglutide and AOM semaglutide, including lifestyle interventions and use of other GLP-1 and non-GLP-1 anti-obesity medications